Jacobio Pharmaceuticals Group Co., Ltd. in 1 story
The narratives 1167.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
1167.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Jacobio develops differentiated oncology molecules against difficult targets such as KRAS and SHP2 that can attract global partners if clinical validation continues.
Bear side
0 storiesNo bear-side stories for 1167.HK yet.